Suven Life Sciences (SUVEN) — Board Meeting

📢 Key Event
Board approved unaudited Q1 FY2026 financial results and preferential warrant issue.

🔄 What Changed
Consolidated net loss widened to ₹1,276.46 lakhs; EPS declined to (4.84); ₹85,764.02 lakhs received for convertible warrants.

🔮 What's Next
Completion of SUVN-502 Phase 3 patient enrollment by September 2026; Phase 3 of SUVN-G3031 initiated in April 2026.

Suven Life Sciences announced unaudited standalone and consolidated financial results for Q1 FY2026, showing a consolidated net loss of ₹1,276.46 lakhs and EPS of (4.84). The board approved the results, a preferential issue of convertible warrants, and ESOP-related share allotments. The filing includes auditor review reports and forward-looking clinical pipeline updates.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUVEN ✨ Ask AI About This

About Suven Life Sciences Limited (SUVEN)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹11,087.76 Cr ROE: -80.9% ROCE: -80.7%

View full SUVEN stock details →

📡 Get AI alerts when SUVEN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUVEN — Free

💡 Ask AI about this filing

"When will SUVN-502 Phase 3 results be reported?" "What is the expected dilution from the convertible warrant issue?" "How will R&D expense trends affect profitability?"

Ask AI Free →

📊 More SUVEN filings

See all SUVEN filings →

🔥 Also filed on 6 August 2026

CHAMBLFERT Chambal Fertilizers & Chemicals Limited Financial Results SUMEETINDS Sumeet Industries Limited Financial Results VISAKAIND Visaka Industries Limited Corporate Action VISAKAIND Visaka Industries Limited Corporate Action SUNPHARMA Sun Pharmaceutical Industries Limited Financial Results VSTL Vibhor Steel Tubes Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUVEN files new disclosures

Track SUVEN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUVEN — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd